In the long-running feud between Regeneron and Amgen around the companies’ competing PCSK9 cholesterol meds, Regeneron has ...

Obicetrapib monotherapy significantly improved the lipid profile of patients with heterozygous familial hypercholesterolemia ...

COPD cases are rising in women. Uncover the latest insights to enhance diagnosis and treatment in your women patients.

Rare Disease Revenue: $2 billion, stable year-on-year. AstraZeneca PLC (NASDAQ:AZN) reported a strong start to 2025 with a 10% increase in total revenue, driven by demand for innovative medicines.

AstraZeneca Plc’s Chief Executive Officer ... including data from its experimental cholesterol drug that significantly reduced “bad” cholesterol in a mid-stage trial. That could be part ...

They have a cholesterol level above 70 ... is it fair to say that under all contemplated scenarios and in light of AstraZeneca's actions over the next two to three years, tariffs are not material ...

AstraZeneca has doubled down on plans to grow its US business as it braces for the country’s potential tariffs on the pharmaceutical industry. The drug maker said it is "firmly committed to investing ...

It does not necessarily reflect the view of The Herald. AstraZeneca has doubled down on plans to grow its US business as it braces for the country’s potential tariffs on the pharmaceutical industry.

AstraZeneca Plc’s Chief Executive Officer Pascal Soriot warned that trade tariffs are not the best way to manage pharmaceuticals and that drugmakers are calling for no additional US levies on ...

(RTTNews) - British drug major AstraZeneca Plc. (AZN.L, AZN) reported Tuesday that its first-quarter profit climbed from last year on sales growth. Further, the company reitereated its fiscal 2025 ...